Takami et al. evaluated the tumour immune microenvironment in 32 germinoma cases, concluding that tumour cells have a 73.5% positivity for PD-L1, while the majority of infiltrating, stained immune cells are PD-1 positive (93.8%), making germinomas a proper candidate for immunotherapy [102]. This evidence concerns the gene CD274 and germinoma.